TWST - Twist Bioscience Corporation
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference, AI systems reaching into laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “In.
Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ: TWST) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,970 shares of the company's stock, valued at approximately $2,157,000. Twist Bioscience comprises
Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ: TWST) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 90,053 shares of the company's stock, valued at approximately $9,265,000. Deutsche Bank AG owned about 0.14% of Twist
Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist.
Twist Bioscience Corp (NASDAQ:TWST) shares surged Wednesday after Anthropic named the company an independent evaluator in a new AI-driven protein design campaign.
Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch goes well beyond chatbots. According to the Wall Street Journal, "Anthropic is targeting a public debut in September or early October, people familiar with its plans said." In those same meetings, the company told some investors that it... The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech)
On August 07, 2026, Twist Bioscience Corp (TWST) shares rose by 6.0%, bringing the current price to $115.67. The stock has experienced significant fluctuations,
Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s share price shot up 10.3% during mid-day trading on Wednesday after Piper Sandler raised their price target on the stock from $85.00 to $115.00. Piper Sandler currently has an overweight rating on the stock. Twist Bioscience traded as high as $111.88 and last traded at $109.72. 593,619
Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve.
Twist Bioscience Corporation (Nasdaq: TWST) (âTwistâ), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten pu
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissio.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (“RSUs”) will be granted to 24 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and Res.
First Trust Advisors LP acquired a new position in Twist Bioscience Corporation (NASDAQ: TWST) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 104,650 shares of the company's stock, valued at approximately $4,973,000. First Trust Advisors LP owned
Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) stock is up on Monday as the company reported its fiscal 2026 third-quarter financial results and raised fiscal 2026 guidance.
Twist Bioscience NASDAQ: TWST reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% from a year earlier, marking its 14th consecutive quarter of growth. The company raised its full-year revenue outlook and said it remains on track to reach adjusted EBITDA breakeven in the fiscal fourth quarter.
Twist Bioscience (TWST) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.47 per share a year ago.
[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights